Brad Norton Gylden Pharma
Brad’s background in Clinical Operations goes back more than three decades. He has worked at various levels in Big Pharma companies and CROs (large and small), as well as running his own consulting business for 13 years, where he supported many small biotech companies in a variety of functions: primarily Clinical Operations, but also regulatory support, pharmacovigilance and due diligence. Most recently, Brad was a Senior Clinical Operations Global Program Director at AstraZeneca, where he supported Phase 3 vaccine studies with the AZ COVID vaccine and planned the implementation of two pre-clinical assets into the clinic.
Brad has successfully led teams that have been responsible for the implementation of 6 clinical development programs from pre-clinical into First in Man trials, with robust Phase I and Phase II study designs, including small molecules, monoclonal antibodies and advanced therapies. These were across multiple clinical indications including GI, Oncology, Anti-Infective, CNS and metabolic disorders including indications requiring identification of specialist bioanalysis markers.
Across his career, having worked in both Sponsor companies and CROs, Brad has full understanding of the key drivers in each, allowing him to bridge the understanding between the two.